Figure 4.
PFS after end-of-treatment analysis. Kaplan-Meier estimates of PFS in all participants after the end of treatment (A) and according to CXCR4 mutational status (B), time on treatment (C), and VGPR attainment (D).

PFS after end-of-treatment analysis. Kaplan-Meier estimates of PFS in all participants after the end of treatment (A) and according to CXCR4 mutational status (B), time on treatment (C), and VGPR attainment (D).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal